Pharmacology Watch
RSSArticles
-
Aspirin and NSAIDs Reduce Colorectal Cancer Risk
Long-term continuous use of low-dose aspirin and long-term use of non-aspirin nonsteroidal anti-inflammatories was associated with reduced colorectal cancer risk.
-
Chronic Sinusitis Recognized as Inflammatory Disease
Evidence supports daily high-volume saline irrigation along with topical corticosteroids as first-line therapy.
-
Liraglutide Effective for Weight Loss in Diabetics
Among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide daily compared with placebo resulted in weight loss over 56 weeks.
-
FDA Actions
FDA fast-tracks approval of a new drug combination for treatment of heart failure; warns about medication errors for two drugs; approves first monoclonal anti-body as second-line treatment for high cholesterol; green lights oral medication for treatment of locally advanced basal cell carcinoma; and approves two new hepatitis C treatments.
-
New Research Weighs Benefits of Triple Therapy for Patients Who Have Undergone PCI
A new study suggests that more is perhaps not better.
-
FDA Actions
The FDA issues a warning on Daytrana, approves cangrelor, signs off on a new drug to fight cystic fibrosis, and green lights a combination drug to treat heart failure.
-
New Drug Reverses Anticoagulant Effect of Dabigatran
The authors conclude that idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.
-
California Mandates Vaccinations for Children
California has passed one of the strictest school vaccination laws in the country, banning the personal exemption option for school-aged children.
-
Liraglutide Helps Non-diabetics Lose Weight
The authors conclude that 3.0 mg of liraglutide given subcutaneously once daily as an adjunct to diet and exercise was associated with clinically meaningful weight loss.
-
FDA Actions
The FDA has approved two drugs for the treatment of diarrhea-predominant irritable bowel syndrome.